By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display

Company News
Novartis AG (NVS)'s Second Copycat Drug Takes Aim at Amgen (AMGN) Again 10/2/2015 6:21:56 AM
Amgen (AMGN) Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe 9/28/2015 7:34:54 AM
Amgen (AMGN) Release: New Treatment Option For Patients With Rare Blood Cancer 9/25/2015 8:51:58 AM
Amgen (AMGN) To Present New Kyprolis (carfilzomib) Data At 15th International Myeloma Workshop 9/24/2015 12:02:20 PM
Former BioVex CEO Who Sold to Amgen (AMGN) for $1 Billion Raises $30 Million for Replimune 9/24/2015 6:15:31 AM
Amgen (AMGN) and Allergan (AGN)'s Avastin Copycat Succeeds in Late Stage Lung Cancer Study 9/23/2015 8:34:23 AM
Amgen (AMGN)'s Two-Pronged Strategy: Cancer and Cholesterol 9/23/2015 6:46:32 AM
In Face of Multiple Patent Cliffs, Amgen (AMGN) Expands Cancer Drugs Portfolio 9/22/2015 6:28:21 AM
FDA Grants Priority Review For Amgen (AMGN)'s Supplemental New Drug Application For Expanded Labeling Of Kyprolis (Carfilzomib) In Relapsed Multiple Myeloma 9/21/2015 11:23:30 AM
Amgen (AMGN)'s Acquisition Of Dezima Pharma And CETP Drug Like Pfizer (PFE)'s '03 Buy Of Esperion (ESPR). Will History Repeat? 9/17/2015 7:00:10 AM